These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8703641)

  • 1. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue.
    Freeman RC; Rodriguez GM; French JF
    AIDS Educ Prev; 1996 Feb; 8(1):58-71. PubMed ID: 8703641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptance of zidovudine (AZT) in early HIV disease: the role of health beliefs.
    Catt S; Stygall J; Catalan J
    AIDS Care; 1995; 7(2):229-5. PubMed ID: 7619875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Seropositive people infected through intravenous drug use: a persistent vulnerability].
    Peretti-Watel P; Spire B; Lert F; Obadia Y;
    Rev Prat; 2005 Dec; 55(19):2093-100. PubMed ID: 16544918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons.
    Stein MD; Piette J; Mor V; Wachtel TJ; Fleishman J; Mayer KH; Carpenter CC
    J Gen Intern Med; 1991; 6(1):35-40. PubMed ID: 1999744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus infection in a Dublin general practice.
    Bury G; O'Kelly F
    J R Coll Gen Pract; 1989 Mar; 39(320):101-3. PubMed ID: 2555484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porphyrin abnormalities in acquired immunodeficiency syndrome.
    O'Connor WJ; Murphy GM; Darby C; Fogarty J; Mulcahy F; O'Moore R; Barnes L
    Arch Dermatol; 1996 Dec; 132(12):1443-7. PubMed ID: 8961872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pneumonia caused by measles in a pregnant woman with HIV antibodies. Response to treatment with immunoglobulins].
    Carmena J; Tornero C; Salcedo M; Perpiñán J; Pons E
    Enferm Infecc Microbiol Clin; 1996; 14(7):456-7. PubMed ID: 8991450
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of alpha interferon levels by AZT treatment in HIV-seropositive patients.
    Buimovici-Klein E; McKinley GF; Lange M; Sonnabend JA; Mohan V; Grieco MH; Cooper LZ
    J Exp Pathol; 1992; 6(1-2):31-9. PubMed ID: 1625038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIDS: AZT for children in extended US trial.
    Lindley D
    Nature; 1989 Nov; 342(6245):10. PubMed ID: 2811993
    [No Abstract]   [Full Text] [Related]  

  • 13. ACTG 175 and Delta.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiretroviral therapy in HIV/AIDS seropositive pregnant women in Cuba].
    González Núñez I; Díaz Jidy M; Pérez Avila J; Mengana Gutiérrez HL
    Rev Cubana Med Trop; 2004; 56(1):70-2. PubMed ID: 15849913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to Bartonella species in inner-city intravenous drug users in Baltimore, Md.
    Comer JA; Flynn C; Regnery RL; Vlahov D; Childs JE
    Arch Intern Med; 1996 Nov; 156(21):2491-5. PubMed ID: 8944742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV follow-up. New data on pathophysiology and treatment of psychiatric disturbances in the course of AIDS].
    Nasierowski T; Matsumoto H
    Psychiatr Pol; 1997; 31(2):197-209. PubMed ID: 9527665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [AZT therapy. Success in HIV-infected children].
    Marcus U
    Fortschr Med; 1989 Jan; 107(3):9-10. PubMed ID: 2920990
    [No Abstract]   [Full Text] [Related]  

  • 20. Providers' HIV prevention discussions with HIV-seropositive injection drug users.
    Wilkinson JD; Zhao W; Santibanez S; Arnsten J; Knowlton A; Gómez CA; Metsch LR;
    AIDS Behav; 2006 Nov; 10(6):699-705. PubMed ID: 16639542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.